Abstract. Streptococcus suis serotype 2 (SS2) is an important pathogen that affects pigs. However, neither its virulence nor its pathogenesis of infection has yet to be fully elucidated. The present study identifies a novel virulence-associated protein E gene (vapE) of SS2. To investigate the importance of vapE in SS2 infection, a vapE knock-out mutant based on SS2 wild-type strain ZY458 was designated 458ΔvapE. 458ΔvapE was generated through homologous recombination, using a combined plasmid with a vapE knock-out fragment and a pSET4s suicide vector. Additionally, the 458ΔvapE strain was transformed by a pAT18 shuttle plasmid containing the vapE gene. A functionally complemented strain for the vapE gene [termed 458ΔvapE (pvapE)] was constructed. Animal experiments demonstrated that mice infected with ZY458 and 458ΔvapE (pvapE) exhibited severe clinical symptoms, including depression, apathy, fever, anorexia, emaciation, swollen eyes and neural disorders, and died within two days of infection. All mice infected with ZY458, and 85% of mice infected with 458ΔvapE (pvapE), died within 2 days of infection. In contrast, mice inoculated with 458ΔvapE exhibited only mild clinical symptoms in the first 2 days following infection, and recovered within a week. A bacterial colonization assay demonstrated the ability of the 458ΔvapE mutant SS2 strain to colonize the heart, liver, spleen, lung and kidney of infected mice. PCR analysis of the vapE gene revealed that functional vapE was detected in virulent strains, but not in avirulent and carrier strains of S. suis SS2. These findings indicate that vapE is important for the pathogenesis of SS2.
Introduction
Streptococcus suis is a major pathogen affecting pigs. It is endemic in countries involved in pig husbandry; however, it may also lead to meningitis, endocarditis, septicemia, arthritis, polyserositis, pneumonia and sudden death in pigs. Occasionally, it may lead to serious zoonotic infections in humans (1) . The large-scale outbreak of human S. suis (type) 2 infection, with the feature of streptococcal toxic shock syndrome, in the Jiangsu and Sichuan provinces of China (2) indicated that S. suis remains a challenge for public health.
Serotype 2 of S. suis (also termed SS2) is considered to be the most virulent of the 33 established serotypes of this pathogen. However, the primary factors contributing to its virulence have yet to be fully elucidated. Previous studies on virulence-associated factors of SS2 have focused primarily on the bacterial capsular polysaccharide, muramidase-released protein, extracellular protein factor and suilysin (3, 4) . Over the last decade, a large number of putative virulence factors associated with SS2 have been investigated (4) , including fibronectin-and fibrinogen-binding proteins (5) , opacity factor of S. suis (6) , peptidoglycan (7), glutamine synthetase (8) , di-peptidyl peptidase IV (9), inosine 5-monophosphate dehydrogenase (10) , trigger factor tig gene (11), virulence-associated gene A (12) , Rgg transcription regulator (13) , surface-associated subtilisin-like protease (14) , catabolite control protein A (15) and superoxide dismutase A (16) . Notably, an 89 K pathogenicity island (PAI) (17) and SalK/SalR (a two-component signal transduction system) (18) have been identified as requisites for the full virulence of ethnic Chinese isolates of highly pathogenic SS2. However, the importance of these proteins in the pathogenicity of SS2, and the pathogenesis of the infection triggered by S. suis, remain to be elucidated.
To identify genes contributing to the virulence of virulent strains, a previous study conducted suppression and subtractive hybridization using a ZY458 virulent SS2 strain and a 13w avirulent SS2 strain (19 but were absent in the avirulent one (19) . Protein E gene (termed vapE) is one of these 42 genes, although it is absent in the non-virulent SS2 strain 1330. The objective of the present study was to investigate the effects of the ∆458VapE mutation on the virulence of SS2.
Materials and methods
Bacterial strains, plasmids and primers. Bacterial strains and plasmids used in the present study are listed in Table Ⅰ . S. suis 2 strains were cultured in brain-heart infusion (BHI) broth (Difco; BD Biosciences, Franklin Lakes, NJ, USA) supplemented with 5% (v/v) calf serum or BHI agar at 37˚C. Escherichia coli strain DH5α was used for cloning purposes and was cultured in Luria broth (LB) or LB agar at 37˚C (20) . When recombinants were screened or cultured, plates or broth were supplemented with appropriate antibiotics at the following concentrations: i) Spectinomycin (Spc), 100 µg/ml for S. suis 2 with plasmid pSET4s and 50 µg/ml for DH5α with plasmid pSET4; ii) ampicillin (Amp), 100 µg/ml for DH5α with plasmid pMD18-T; iii) erythromycin (Ery), 8 µg/ml for S. suis 2 with plasmid pAT18 and 150 µg/ml for DH5α with plasmid pAT18 (all antibiotics from Sigma-Aldrich, St. Louis, MO, USA). DNA extraction, cloning, transformation, and other molecular techniques used in the present study were implemented following protocols described previously (20) . All primer synthesis and DNA sequencing were outsourced to Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA).
Construction of the vapE mutant strain.
The primers used in the current study are presented in (21) to generate the pSET4s::ΔvapE suicide plasmid. The resultant plasmid was confirmed by DNA sequencing and transfected into a ZY458 SS2 strain to screen for deletion mutants as described by Takamatsu et al (22) . Subsequently, the SS2 strain ZY458 was electrotransfected with pSET4s::ΔvapE using the ECM 399 electroporation system (BTX Harvard Apparatus, Inc., Holliston, MA, USA) at 2,000 V, and cultured at 28˚C in the presence of Spc to select the recombinant. The resultant ZY458 (pSET4s::ΔvapE) cells were cultured in BHI broth with Spc at 28˚C until the early logarithmic growth phase, and then were shifted to 37˚C and incubated for an additional 10 h. Subsequently, the cultures were diluted and spread onto BHI agar plates without antibiotic and incubated overnight at 37˚C. The cultures were screened for mutants that had lost the vectors and had exchanged their wild-type allele for a genetic segment containing the ΔvapE gene as a consequence of homologous recombination via a double cross-over. A resultant 458ΔvapE mutant strain was verified by PCR amplification with the primers VapE-5/VapE-R and further confirmed by DNA sequencing. The PCR cycle protocol, performed on Techgene FTGENE2D thermocycler, was as follows: i) Initial denaturation at 94˚ for 3 min; ii) 30 cycles of 94˚C for 30 sec, 50˚C for 30 sec and 72˚C for 40 sec; and iii) a final elongation step at 72˚C for 10 min.
Functional complemented vapE mutant strain. To generate a functionally complemented strain of 458ΔvapE, the structural gene of vapE with its promoter sequence (from 320 bp upstream of the start codon to 439 bp downstream of the stop codon) was amplified using primers VapE-F and VapE-R. PCR was performed on a Techgene FTGENE2D thermocycler under the following conditions: i) Initiation and elongation, 3 min at 94˚; ii) 30 cycles of denaturation for 30 sec at 94˚, annealing for 30 sec at 50˚C; and iii) elongation for 2 min at 72˚C; and a final elongation step at 72˚C for 10 min. The PCR product (2,292 bp) was purified using the DNA Gel Extraction kit and subsequently cloned into pMD18-T to generate the plasmid, pMD18-T::vapE. The vapE fragment was then subcloned into shuttle vector pAT18. The resultant plasmid was verified by DNA sequencing, and subsequently used to electrotransfect the mutant strain 458ΔvapE using the ECM 399 electroporation system, as described above (BTX Harvard Apparatus, Inc.), which was plated onto BHI agar supplemented with Ery to screen for the complemented strain, 458ΔvapE (pvapE).
Bacterial growth curve. Wild-type strain S. suis 2 ZY458, mutant strain 458ΔvapE and complemented strain 458ΔvapE (pvapE) were separately inoculated into 100 ml BHI broth and incubated at 37˚C. Samples of culture were monitored by spectrophotometry using a T6 UV spectrophotometer (Beijing Purkinje General Instrument Co., Ltd, Beijing, China). The absorbance was measured at 600 nm in a quartz cuvette (Beijing Purkinje General Instrument Co., Ltd.) at 1 h intervals. BHI broth minus the inoculation of bacteria served as a blank. (23) . The bacterial cultures were serially diluted in BHI broth and plated onto BHI agar plates in order to determine the colony forming unit (CFU)/ml. The working cultures for experimental infection were adjusted to a final concentration of 1x10 9 CFU/ml. Female BALB/c mice (age, 4 weeks; weight, 13-14 g) were housed at 24±1˚C and 60% relative humidity in a 12-h light/dark cycle with access to food and water ad libitum. They were randomly divided into four groups (12 mice/group), and individual groups were injected intraperitoneally (i.p.) with 100 µl of the ZY458 wild-type strain, ZD89 carrier strain, 458ΔvapE mutant strain or 458ΔvapE (pvapE) complemented strain cultures. The animals were monitored daily for 1 week for mortality and clinical signs, including depression, swollen eyes, ruffled hair, lethargy and nervous symptoms. Tissues of the heart, liver, spleen, lung and kidney from infected mice (12 mice/group) were harvested for detection of the SS2 bacteria by plating onto BHI agar plates. Positive cultures were confirmed by PCR using VapE-F and VapE-R primers (Table II) .
Bacterial colonization assay.
To evaluate the pathogenicity of SS2, the capacity of the bacteria to colonize the tissues of the heart, liver, spleen, lung and kidney of infected mice was analyzed using a colonization assay. Further BALB/c (13-14 g) mice were randomly divided into three groups (nine mice/group) and injected i.p. with 1x10 8 CFU/mouse of one of the ZY458, ZD89 or 458ΔvapE strains. One mouse from each group was euthanized by cervical dislocation at 12, 24 and 36 h post-infection, and the tissues were collected and ground with an electric pestle (Tiangen Biotech Co., Ltd., Beijing, China) in 0.9% NaCl (0.03 g tissue/ml). The supernatants were diluted 10-fold and plated onto BHI agar plates. Following an overnight incubation, the bacterial colonies were counted and the data were expressed as CFU/g of tissue, as described previously (24) .
Distribution analysis of the vapE gene by PCR. The primers
VapE-F and VapE-R were designed on the basis of the published sequence of the SS2 strain, 05ZYH33 (GenBank accession no. NC_009442), to detect the vapE gene from the genomic DNA of SS2 strains ZY458, SP3, SP6, 1330, ZD89, B22, B3 and SP8 by PCR. 16S rDNA served as the reference gene. Each reaction was conducted using a 25 µl mixture containing 2.5 µl 10X buffer, 25 pmol each primer, 2 mM each deoxynucleoside triphosphate, 2.5 units Taq polymerase and 2.5µl supernatant of denatured bacteria. The PCR was performed with Techgene FTGENE2D thermocycler, under the following conditions: i) Initiation and elongation for 3 min at 94˚; ii) 30 cycles of denaturation for 30 sec at 94˚, annealing for 30 sec at 50˚C and elongation for 2 min at 72˚C; and iii) a final elongation step at 72˚C for 10 min. Amplicons were visualized by running at 100 V for 30 min on a 1% agarose gel containing ethidium bromide (Takara Biotechnology Co., Ltd.). A DL2000 DNA ladder (Takara Biotechnology Co., Ltd.) was used as a size marker.
Results

Generation of vapE mutant.
A vapE deletion mutant strain, 458ΔvapE, was generated by a homologous replacement method using ZY458 as the parent strain. The vapE gene knock-out mutant strain was confirmed by PCR (Fig. 1) .
Comparing the nucleotide sequences using basic local alignment search tool (BLAST) searching revealed that a 194 bp segment of the vapE gene (from 1 to 194 nt of the Figure 1 . Identification of SS2 458ΔvapE mutants and the complemented strain 458ΔvapE (pvapE) using a polymerase chain reaction assay. M is the DL2000 DNA marker, and lanes 1 to 3 are PCR products amplified from SS2 strains 458ΔvapE, 458ΔvapE (pvapE) and ZY458, respectively. Table Ⅰ . M is the DL2000 DNA marker (Takara). Lanes 1 to 8 are PCR products amplified from strains ZY458, SP3, SP6, 1330, ZD89, B22, B3 and SP8, respectively. The amplified vapE PCR fragment is 2292 bp. PCR, polymerase chain reaction. vapE coding sequence) had been deleted without alteration of the remaining sequence.
Generation of a functional complemented ΔvapE mutant.
The PCR-amplified structural gene of vapE was cloned into a pAT18 shuttle vector. The resultant plasmid was confirmed by PCR ( Fig. 1 ) and designated as pAT18::vapE, which was then electrotransfected into 458ΔvapE cells to produce the complemented strain, 458ΔvapE (pvapE). A BLAST analysis of the nucleotide sequences in the National Center for Biotechnology Information database with the vapE gene confirmed that the amplified 2,292 bp fragment was identical with the other strains.
Bacterial growth rates. To determine whether the deletion of the vapE gene leads to a defect in bacterial growth, the growth characteristics of wild-type SS2 strain ZY458, the vapE deletion mutant, 458ΔvapE, and the complemented strain, 458ΔvapE (pvapE), were compared at 37˚C in BHI broth. The optical density values of the bacterial cultures at 600 nm were measured. The growth curves indicated that the growth rates of the mutant strains 458ΔvapE and 458ΔvapE (pvapE) were similar to that of the wild-type strain, ZY458 (Fig. 2) .
The virulence of the ΔvapE mutant is attenuated in mice.
To further assess the effect of vapE deletion on the pathogenesis of SS2, four groups of mice were infected with one of the SS2 wild-type strain ZY458, the carrier strain, ZD89, or the mutant strains, 458ΔvapE or 458ΔvapE (pvapE). The results indicated that all mice infected with wild-type SS2 exhibited severe clinical symptoms, including depression, apathy, fever, anorexia, emaciation, swollen eyes and neural disorders, and died within 2 days of infection (Table Ⅲ) . Similarly, animals infected with the complemented strain 458ΔvapE(pvapE) developed severe clinical symptoms and 83.3% of the mice died 2 days post-infection. By contrast, 100% of the mice infected with mutant strain 458ΔvapE exhibited only mild clinical symptoms in the first 2 days post-infection, and recovered fully within a week. None of the mice injected with ZD89 developed any clinical symptoms. Furthermore, SS2 bacteria were recovered from the organs of mice infected with ZY458 and 458ΔvapE (pvapE). However, no bacteria were detected in the heart, liver, spleen, lung or kidney of any mice infected with 458ΔvapE or ZD89 over a test period of 7 days post-infection (data not shown).
To further evaluate the virulence attenuation of 458ΔvapE, a bacterial colonization assay was performed. As indicated in Table Ⅳ , a reduction in clone-forming efficiency was observed in the infected mice. Mice infected with ZY458 died within 36 h, in contrast, mice infected with 458ΔvapE remained alive with 10 5 -10 6 CFU/g of tissue.
Distribution analysis of the vapE gene in various S. suis 2 strains. To determine whether the vapE gene exists only in virulent strains of SS2, PCR amplification of the vapE gene was performed using primers of VapE-F and VapE-R (Table Ⅱ) . A 2,292 bp portion of the target fragment was amplified from the virulent strains (ZY458, SP3, SP6), but not from any of the avirulent (1330) and carrier strains that were investigated (ZD89, B22, B3 and SP8) (Fig. 3) . Percentage of mice from which SS2 was isolated
Morbidity ( ZY458 To investigate the role of the vapE gene in the pathogenesis of SS2, a vapE in-frame deletion mutant of wild-type strain ZY458 was generated using a gene knock-out, and the impact of the vapE deletion on the virulence of S. suis 2 was assessed in a mouse infection model. The current findings indicated that mice infected with the ZY458 wild-type strain or the 458ΔvapE (pvapE) complemented strain presented severe clinical symptoms, including body weight loss, and died within 2 days of infection, suggesting that the complemented strain retained the virulence of the wild-type strain. By contrast, mice inoculated with the vapE deletion mutant developed only mild clinical signs, with marginal weight loss in the first 2 days post-infection, and they recovered fully within a week. This indicates that deletion of the vapE gene in the ZY458 virulent strain leads to reduced pathogenicity of SS2 in mice. Together with the molecular evidence that the vapE gene is present only in virulent SS2 strains, these findings suggest that the vapE gene is critical for the pathogenicity of S. suis 2.
The exact function of the vapE gene in SS2 remains unclear; however, the vapE protein was predicted to be cytoplasmic by the Cell-Ploc package (26) . The corresponding gene products in S. suis strains P1/7, BM407 and SC84 have been annotated as 'putative phage primase' in GenBank, and as 'virulence-associated protein E' in other S. suis strains. In a previous study, Wei et al (27) identified various putative PAIs of S. suis 2, with the vapE gene located in PAI4. Notably, this putative PAI only existed in virulent S. suis 2 strains and was able to encode phage integrases, certain hypothetical proteins, phage protein and tRNA. On the basis of its original phage elements, vapE has been suggested to be from a bacteriophage that integrated into the S. suis 2 genome through a horizontal gene transfer (28) . Its absence may reduce the expression of other virulence-associated proteins in PAI4, thus reducing the overall pathogenicity of S. suis 2. As a result, animals exhibited mild clinical symptoms and recovered fully after 2 days.
In conclusion, the results reported in the present study clearly indicate that vapE is associated with the pathogenicity of S. suis 2. Although its function requires further investigation, this finding may contribute to the understanding of the pathogenesis of S. suis 2 and may help in the development of novel strategies against S. suis infections. Further investigation will require research into the transcriptome of S. suis ZY458 and 458ΔvapE.
